Decibel Therapeutics, Inc. DBTX

Full chart Compare
Set alert

Price alert · DBTX

All alert types
4.91 +4.91

Day range unavailable

52-week range unavailable

Analyst view

Consensus: buy

Buy
Price target (mean) 14.40 +193.3% upside
Target (low)
2.00
Target (mean)
14.40
Target (high)
23.00
Ratings (-1m) 6 5 buy · 1 hold · 0 sell
  • Strong buy2
  • Buy3
  • Hold1
  • Sell0
  • Strong sell0

Recommendation trend

  • 1 month ago 6
  • 2 months ago 6

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

DBTX analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.50-0.77 – -0.28-0.68+26.5%4.79M0.0%5
Next quarter-0.59-0.78 – -0.28-0.64+7.8%2.19M0.0%5
Current year-2.14-2.79 – -1.12-2.52+15.1%11.35M0.0%5
Next year-1.87-2.69 – -0.77-2.14+12.6%5.00M-55.9%5

Upgrades and downgrades

The latest rating changes

DBTX analyst upgrades and downgrades
DateFirmActionFromTo
Jun 6, 2023HC Wainwright & Co.ReiteratedBuyBuy
May 12, 2023HC Wainwright & Co.ReiteratedBuyBuy
Mar 15, 2023SVB LeerinkDowngradeOutperformMarket Perform
Mar 15, 2023HC Wainwright & Co.Reiterated—Buy
Feb 13, 2023HC Wainwright & Co.Reiterated—Buy
Jan 23, 2023SVB LeerinkMaintained—Outperform
Nov 10, 2022CitigroupMaintained—Buy
May 17, 2022CitigroupMaintained—Buy
Mar 21, 2022BarclaysMaintained—Overweight
Dec 2, 2021JonesTradingInitiated—Buy
Nov 15, 2021HC Wainwright & Co.Initiated—Buy
Nov 10, 2021SVB LeerinkMaintained—Outperform
Oct 22, 2021BairdInitiated—Outperform
May 14, 2021SVB LeerinkMaintained—Outperform
Mar 9, 2021CitigroupInitiated—Buy
Mar 9, 2021BMO CapitalInitiated—Outperform
Mar 9, 2021BarclaysInitiated—Overweight
Mar 9, 2021SVB LeerinkInitiated—Outperform